Clinical outcomes after treatment with direct-acting antivirals: not all concern hepatocellular carcinoma risk

Elton Dajti, Federico Ravaioli, Davide Festi, Antonio Colecchia


The introduction of direct-acting antivirals (DAAs) has revolutionized the natural history of chronic hepatitis C virus (HCV) infection, as the high rates of sustained virologic response (SVR) have been associated with improved survival in both cirrhotic and noncirrhotic patients (1). However, the risk of hepatocellular carcinoma (HCC) after DAA treatment has been a hot topic in the literature of the last few years, especially after two initial studies reporting unexpectedly high rates of both HCC occurrence and recurrence after SVR (2,3).